These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 9447899

  • 1. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J, Blanquer J, Cobo L, Corcia S, Daguerre M, de Latorre FJ, León C, Del Nogal F, Net A, Rello J.
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing LO, Nyström PO, Anséhn S, Bäckstrand B, Skau T.
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [Abstract] [Full Text] [Related]

  • 4. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ.
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
    [Abstract] [Full Text] [Related]

  • 5. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C, Belgian Multicenter Study Group.
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [Abstract] [Full Text] [Related]

  • 6. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
    Zanetti G, Harbarth SJ, Trampuz A, Ganeo M, Mosimann F, Chautemps R, Morel P, Lew D, Zimmerli W, Lange J, Glauser M.
    Int J Antimicrob Agents; 1999 Feb; 11(2):107-13. PubMed ID: 10221413
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
    Embil JM, Soto NE, Melnick DA.
    Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
    [Abstract] [Full Text] [Related]

  • 9. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE.
    Surg Infect (Larchmt); 2005 Aug; 6(3):269-82. PubMed ID: 16201937
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
    Shah PM, Heller A, Fuhr HG, Walther F, Halir S, Schaumann R, Böhme A, Jung B, Köhler A, Lips-Schulte C, Stille W.
    Infection; 1996 Aug; 24(6):480-4. PubMed ID: 9007599
    [Abstract] [Full Text] [Related]

  • 14. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, Moretti AM, De Vizzi GB, Petraglia A, Mancini P, Atzeni R, Fogliani V, Giura R, Paradisi F.
    Drugs Exp Clin Res; 1999 Aug; 25(6):243-52. PubMed ID: 10713862
    [Abstract] [Full Text] [Related]

  • 15. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE, Holloway WJ, Geckler RW.
    Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
    [Abstract] [Full Text] [Related]

  • 16. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
    Romanelli G, Cravarezza P.
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
    Hou F, Li J, Wu G, Zheng B, Chen Y, Gu J, Wang H, Huo L, Xue X, Jia C, Yin Y, Tian X, Ren S.
    Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
    [Abstract] [Full Text] [Related]

  • 20. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.
    Brismar B, Akerlund JE, Sjöstedt S, Johansson C, Törnqvist A, Bäckstrand B, Bång H, Andåker L, Gustafsson PO, Darle N, Angerås M, Falk A, Tunevall G, Kasholm-Tengve B, Skau T, Nyström PO, Gasslander T, Hagelbäck A, Olsson-Liljequist B, Eklund AE, Nord CE.
    Scand J Infect Dis; 1996 Dec; 28(5):507-12. PubMed ID: 8953683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.